X-c(=x)-x Containing (e.g., Carbonic Acid Ester, Thiocarbonic Acid Ester, Etc.) (x Is Chalcogen) Patents (Class 514/512)
-
Publication number: 20120034174Abstract: The present invention provides a surfactant product in the form of a solid comprising a surfactant, sodium carbonate and cream of tartar.Type: ApplicationFiled: February 19, 2010Publication date: February 9, 2012Inventors: Mark Constantine, Margaret Joan Constantine, Helen Elizabeth Ambrosen
-
Publication number: 20120014884Abstract: The present invention discloses novel uses of specific menthol-derivative compounds of Formula 1, and compositions thereof, for methods of providing oral and systemic health care benefits, and methods of up-regulating or down-regulating periodontal disease metabolites: Formula 1 wherein, X is an oxygen atom or an NH radical; and R is an unsubstituted or substituted aryl or aliphatic radical. In some embodiments, the oral and systemic health care benefits include biofilm anti-attachment, anti-inflammation, anti-oxidant, anti-bone loss, and anti-microbial benefits. In some embodiments, the periodontal disease metabolites correspond to healthy and/or diseased oral status and allow differential diagnosis of oral health.Type: ApplicationFiled: April 1, 2009Publication date: January 19, 2012Applicant: Colgate-Palmolive CompanyInventors: Harsh M. Trivedi, Tao Xu, Davide Miksa, Cortney Worrell, Chanda Macias, Ying Yang, Yanan Hu
-
Publication number: 20120010168Abstract: A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X?C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.Type: ApplicationFiled: November 3, 2009Publication date: January 12, 2012Inventors: Jeffrey Laskin, Diane Heck, Mou-Tuan Huan, Karine Fabio, C. Jeffrey Lacey, Sherri Young, Pramod Mohanta, Christophe Guillon, Ned Heindel
-
Publication number: 20120004232Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: ApplicationFiled: September 8, 2011Publication date: January 5, 2012Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Akito YASUHARA, Kazunari SAKAGAMI, Hiroshi OHTA, Atsuro NAKAZATO
-
Publication number: 20120003281Abstract: Use of a powder comprising more than 40% by weight of sodium bicarbonate, for its acaricidal effects in the storage of cereals.Type: ApplicationFiled: September 14, 2011Publication date: January 5, 2012Applicant: SOLVAY (SOCIETE ANONYME)Inventors: Jean-Philippe PASCAL, Nicolas PALANGIE
-
Publication number: 20110294879Abstract: Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and/or autism, comprising administering a prodrug of acamprosate to a subject suffering therefrom, wherein, in certain embodiments, the acamprosate prodrugs comprise compounds of Formula (I).Type: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Applicant: XENOPORT, INC.Inventors: Bernd Jandeleit, Mark A. Gallop, Peter A. Virsik, David J. Wustrow
-
Publication number: 20110245262Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 20, 2007Publication date: October 6, 2011Inventors: Lijun Sun, Keizo Koya, Shoujun Chen, Zachary Demko, Zhi-Qiang Xia
-
Publication number: 20110218176Abstract: The present invention relates to prevention of congenital deformations. The invention further relates to cancer inhibition and prevention. The invention further relates to methods and compositions to modulate, antagonize, or agonize disparate signaling pathways that may converge to regulate patterning events and gene expression during prenatal development, post-natal development, and during development in the adult organism. The invention also relates to activators or deactivators of pyruvate kinase M2 (PKM2) for the treatment, prevention, or amelioration of diseases related to PKM2 function.Type: ApplicationFiled: May 6, 2011Publication date: September 8, 2011Inventor: Barbara Brooke Jennings-Spring
-
Publication number: 20110218177Abstract: The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.Type: ApplicationFiled: September 21, 2009Publication date: September 8, 2011Inventors: Sander G. Mills, Amjad Ali, Cameron Smith
-
Publication number: 20110217262Abstract: A method of treating an ocular surface disorder in a subject in need of such treatment is provided. The method includes exposing conjunctival tissue of the subject to an effective amount of a vasopermeability agent that increases conjunctival vascular permeability. In some embodiments, the agent is a nitric oxide donor, which may be in a sustained release form. A method of screening a substance for treating an ocular surface disorder is also provided.Type: ApplicationFiled: March 7, 2011Publication date: September 8, 2011Inventors: Julia A. Kornfield, Robert H. Grubbs, Choon Woo Lee, Daniel Schwartz, Phoebe Lin, Keith Duncan
-
Publication number: 20110184061Abstract: Disclosed herein are thiocolchicine and colchicine analogs and derivatives suitable for use as a muscle relaxant, an anti-inflammatory agent, an anti-gout agent, an anti-proliferative agent, or an anti-cancer agent; methods of making the compounds, and compositions comprising the compounds.Type: ApplicationFiled: January 20, 2011Publication date: July 28, 2011Inventors: Kurt R. Nielsen, Rajesh Manchanda, Tong Sun, Shawn G. Watson
-
Patent number: 7977305Abstract: The present invention relates to hormone coating layers having desirable hormone delivery characteristics and product lifetime. In one embodiment, the invention is a hormone composition including a substrate having an external surface, and a coating layer disposed on the external surface. The coating layer preferably includes a polymer web, and from about 1 wppm to about 100,000 wppm of a hormone comprising a terpene dispersed throughout the polymer web. The invention also relates to methods for making hormone coating materials of the present invention. The coating compositions of the present invention preferably are implemented in human and animal food packaging materials in order to safely and efficiently protect the foodstuffs contained therein from insect infestation.Type: GrantFiled: May 16, 2007Date of Patent: July 12, 2011Inventors: Timothy Jon Leeper, Joy Michelle Thomas, Amy Marie Nichols
-
Publication number: 20110152364Abstract: Provided are compositions for repelling fluids comprising a volatile liquid carrier, a powder-feel agent and less than 5 weight % of an ester selected from the group consisting of formula I, formula II, formula III, and combinations of two or more thereof: wherein R1, R2, R3, R5, R6, R8 and R9 are independently linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkyl or alkenyl groups, R4 is a linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkylene or alkenylene moiety, and R7 is a linear or branched, substituted or unsubstituted, saturated or unsaturated C3-22 moiety, the composition being substantially anhydrous. Also provided are methods of improving dryness and/or comfort associated with the intimate area, as well as, kits comprising the composition and an absorbent article.Type: ApplicationFiled: December 18, 2009Publication date: June 23, 2011Inventors: Kofi A. Bissah, Ricardo De Oliveira, Saurabh Desai, Joseph J. LiBrizzi, Thong Ngyuen, Shoba Pillai
-
Patent number: 7951407Abstract: A method of stimulating or enhancing an ornithine-urea cycle in ruminant gut tissues, which entails either feeding to a ruminant an effective amount of a ruminant feed or feed supplement containing an effective amount of a compound which stimulates activity of one or more enzymes required in the ornithine-urea cycle.Type: GrantFiled: October 20, 2006Date of Patent: May 31, 2011Assignee: University of MarylandInventor: Brian James Bequette
-
Publication number: 20110071178Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.Type: ApplicationFiled: April 16, 2010Publication date: March 24, 2011Applicant: Northeastern UniversityInventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
-
Publication number: 20110052694Abstract: Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.Type: ApplicationFiled: August 31, 2010Publication date: March 3, 2011Applicant: ALLTRANZ INC.Inventors: Audra Lynn Stinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffery Lynn Howard, Dana Carmel Hammell
-
Publication number: 20110039701Abstract: The invention relates to novel compounds of the formula (I) in which X, Y, Z, A, B and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates 33 and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as insecticides and/or acaricides and/or for preventing unwanted plant growth.Type: ApplicationFiled: March 30, 2010Publication date: February 17, 2011Applicant: Bayer CropScience AGInventors: Alfred ANGERMANN, Guido Bojack, Reiner Fischer, Stefan Lehr, Jan Dittgen, Dieter Feucht, Isolde Häuser-Hahn, Christopher Hugh Rosinger, Arnd Voerste
-
Publication number: 20110039874Abstract: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.Type: ApplicationFiled: April 16, 2010Publication date: February 17, 2011Applicant: Northeastern UniversityInventors: Alexandros Makriyannis, Spyridon P. Nikas, Shakiru O. Alapafuja, Vidyanand G. Shukla
-
Publication number: 20110028544Abstract: Catechol protected levodopa diester prodrugs pharmaceutical, compositions comprising catechol protected levodopa diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.Type: ApplicationFiled: October 14, 2010Publication date: February 3, 2011Applicant: XenoPort, Inc.Inventors: Jia-Ning Xiang, Cindy X. Zhou, Fenmei Yao, Mark Q. Nguyen
-
Patent number: 7879357Abstract: The invention relates to a pharmaceutical composition in the form of a hydrogel that comprises a carboxylic acid diester, a C2-C4 alkyl alcohol, an active ingredient and a polymer matrix. The invention also relates to the use of a carboxylic acid diester as a transdermal permation enhancer for an active ingredient in a pharmaceutical composition in the form of a hydrogel, whereby the composition comprises a polymer matrix and a C2-C4 alkyl alcohol. The invention also relates to a sweat-resistant composition in the form of a hydrogel, which comprises an acrylic polymer in combination with a cellulose derivative.Type: GrantFiled: April 28, 2004Date of Patent: February 1, 2011Assignee: Bayer Schering Pharma AGInventor: Patrick Franke
-
Publication number: 20110021624Abstract: Disclosed are a series of ?-amino-N-substituted amide compounds having a structure of the following formula, the pharmaceutically acceptable salts thereof, and the pharmaceutical composition comprising the same. The ?-amino-N-substituted amide compounds or the pharmaceutically acceptable salts thereof according to the present invention have anti-tumor and/or anti-cancer activities in vivo and in vitro, can effectively depress the growth of various tumor cells and/or cancer cells, and thus can be used in preparing drugs for treating tumors and/or cancers.Type: ApplicationFiled: December 11, 2008Publication date: January 27, 2011Inventors: Fajun Nan, Jia Li, Jian Ding, Gang Liu, Chuanming Xie, Zehong Miao, Wanyi Tai
-
Publication number: 20100273875Abstract: A composition for external application to skin, containing a compound represented by formula (I) or a salt thereof, and/or a quaternary ammonium salt represented by formula (II): wherein R1 is a substituted or unsubstituted, linear or branched chain alkyl group having 2 to 25 carbon atoms; X is —CO—NH—, —O—CO—O—, —NH—CO—, —CO—O—, —O—CO— or —O—; Y is a substituted or unsubstituted alkylene group having 1 to 4 carbon atoms; R2 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R3 is an alkyl group having 1 to 4 carbon atoms; R2 and R3 are the same as or different from each other; R4, R5 and R6, which may the same as or different from each other, each are an alkyl group having 1 to 4 carbon atoms; and A? is a counter ion.Type: ApplicationFiled: November 5, 2008Publication date: October 28, 2010Applicant: KAO CORPORATIONInventors: Yasuto Suzuki, Kazue Tsukahara
-
Publication number: 20100227791Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.Type: ApplicationFiled: January 7, 2010Publication date: September 9, 2010Inventors: Gianfranco Peluso, Menotti Calvani
-
Publication number: 20100124543Abstract: The present invention relates to prodrugs of a class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of prodrugs of HIV aspartyl protease inhibitors characterized by favorable aqueous solubility, high oral bioavailability and facile in vivo generation of the active ingredient. This invention also relates to pharmaceutical compositions comprising these prodrugs. The prodrugs and pharmaceutical compositions of this invention are particularly well suited for decreasing the pill burden and increasing patient compliance. This invention also relates to methods of treating mammals with these prodrugs and pharmaceutical compositions.Type: ApplicationFiled: July 16, 2009Publication date: May 20, 2010Applicant: Vertex Pharmaceuticals IncorporatedInventors: Roger Dennis Tung, Michael Robin Hale, Christopher Todd Baker, Eric Steven Furfine, Istvan Kaldor, Wieslaw Mieczylaw Kazmierski, Andrew Spaltenstein
-
Publication number: 20100063144Abstract: There is provided a compound of formula (I) wherein R1a, R2a, R3, X1 to X6, a, b and c have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, inhibitors of HDAC enzyme activity, and thus, in particular, in the treatment of conditions where inhibition of HDAC enzyme activity is required.Type: ApplicationFiled: October 24, 2007Publication date: March 11, 2010Applicant: IMPERIAL INNOVATIONS LTDInventors: Eric Ofori Aboagye, David Michael Vigushin, Wendy Vigushin
-
Publication number: 20100048699Abstract: A compound of formula I where the substituents have the meanings assigned to them in claim 1, compositions comprising a compound of formula (I) and the use of such compounds and/or compositions controlling insects, acarines, nematodes or molluscs.Type: ApplicationFiled: June 29, 2007Publication date: February 25, 2010Applicants: SYNGENTA CROP PROTECTION, INC., SYNGENTA LIMITEDInventors: Juergen Harry Schaetzer, Christoph Luthy, William Lutz, Donn Warwick Moseley, Anthony Cornellius O'Sullivan
-
Patent number: 7645792Abstract: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.Type: GrantFiled: June 26, 2007Date of Patent: January 12, 2010Assignee: XenoPort, Inc.Inventors: Mark Gallop, Feng Xu
-
Patent number: 7625948Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.Type: GrantFiled: February 28, 2003Date of Patent: December 1, 2009Assignee: Japan Tobacco Inc.Inventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
-
Publication number: 20090286763Abstract: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.Type: ApplicationFiled: May 18, 2009Publication date: November 19, 2009Applicant: XenoPort, Inc.Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar
-
Publication number: 20090285881Abstract: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.Type: ApplicationFiled: April 16, 2009Publication date: November 19, 2009Applicant: ABBOTT LABORATORIESInventors: Prasad A. Dande, Todd M. Hansen, Robert D. Hubbard, Carol K. Wada, Lu Tian, Xiaobin Zhao
-
Publication number: 20090209585Abstract: The present invention relates to a cycloalkene derivative represented by the formula (I): wherein each symbol is as defined in the specification, a pharmaceutical agent containing the derivative, and a production method thereof. The cycloalkene derivative of the present invention has high solubility in water and is suitable for use as an injection.Type: ApplicationFiled: July 6, 2007Publication date: August 20, 2009Inventors: Takashi Ichikawa, Tomoyuki Kitazaki, Norikazu Tamura
-
Patent number: 7576127Abstract: Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting are disclosed herein.Type: GrantFiled: August 21, 2006Date of Patent: August 18, 2009Assignee: XenoPort, Inc.Inventors: Mark A. Gallop, Feng Xu
-
Publication number: 20090203776Abstract: Menthol propyleneglycal-carbonate, analogs thereof and compositions containing such compounds are administered to mammals, preferably humans, to produce anti-inflammatory or anti-angiogenic effects.Type: ApplicationFiled: September 23, 2005Publication date: August 13, 2009Inventor: Jonathan R. Matias
-
Publication number: 20090181893Abstract: The present invention provides compositions and methods for treating otic disorders. More specifically, the present invention describes the use of agents that down-regulate expression of Tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the ear.Type: ApplicationFiled: March 2, 2009Publication date: July 16, 2009Applicant: ALCON, INC.Inventor: Najam A. Sharif
-
Publication number: 20090149533Abstract: The invention provides novel omega-3 ester-based oil solutions of fenofibrate. These solutions are substantially free of any food effect, effective in small volumes, and readily bioavailable. Notably, because the solutions of the invention contain an omega-3 ester-based oil as the major ingredient, they not only provide an antihyperlipidemic effect due to the fenofibrate active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof.Type: ApplicationFiled: August 4, 2005Publication date: June 11, 2009Applicant: TransForm Pharmaceuticals, Inc.Inventors: Orn Almarsson, Pasut Ratanabanangkoon, Julius Remenar, Hector Guzman
-
Publication number: 20090143340Abstract: Pyrocatechin derivatives of formula I wherein R illustrates a group of formulae Ia, Ib, Ic or Id R1 is 4-halogen-but-2-enyl, R2 is lower alkyl or cycloalkyl, R3 is lower alkoxy and R4 is lower alkoxy lower alkoxy, or, where R is a group of formula (Ia), it is hydroxy, hydroxy lower alkoxy or a group of formula Ie R5 is reactive esterified hydroxy, R6 is azido and R7 is lower alkyl, lower alkenyl, cycloalkyl or aryl lower alkyl, and their salts, are valuable intermediates in the production of active ingredients for medicaments.Type: ApplicationFiled: July 10, 2006Publication date: June 4, 2009Inventors: Gottfried Sedelmeier, Kurt Nebel, Siem Jacob Veenstra, Janos Zergenyi
-
Patent number: 7538140Abstract: A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1?) (wherein R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; X is —COO— or —CON(R10)—; R3 and R4 are each hydrogen atom, C1-C6alkyl or C1-C6alkoxy, etc.; R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; R8 and R9 are each independently hydrogen atom, C1-C6alkyl, —CON(R18)(R19) or —COO(R20), etc.; ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; Alk1 and Alk2 are each independently alkanediyl, etc.; l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.Type: GrantFiled: February 28, 2003Date of Patent: May 26, 2009Assignee: Japan Tobacco IncInventors: Atsushi Hagiwara, Yasuhiro Ohe, Naoya Odani, Shizue Watanabe, Taku Ikenogami, Takashi Kawai, Kenya Madono, Toshio Taniguchi
-
Publication number: 20090074872Abstract: Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days.Type: ApplicationFiled: November 20, 2008Publication date: March 19, 2009Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventors: Kristin Anne Arnold, Hengsheng Feng
-
Publication number: 20090076141Abstract: Methods of treating alcohol neuropathic pain in a patient comprising orally administering a therapeutically effective amount of a propofol prodrug having high oral bioavailability are disclosed.Type: ApplicationFiled: September 12, 2008Publication date: March 19, 2009Applicant: XenoPort, Inc.Inventor: Peter A. Virsik
-
Publication number: 20090042911Abstract: The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.Type: ApplicationFiled: September 29, 2008Publication date: February 12, 2009Inventors: John S. Pears, Ali Raza, Howard G. Hutchinson, Dennis Schneck, Takahiko Baba, Akira Touchi, Yoshitaka Yamaguchi
-
Publication number: 20090035379Abstract: The invention provides fenofibrate compositions comprising granulates, where the granulates comprise micronized fenofibrate.Type: ApplicationFiled: June 23, 2008Publication date: February 5, 2009Applicant: Cabinet HirschInventors: Andre Stamm, Pawan Seth
-
Publication number: 20090036523Abstract: Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.Type: ApplicationFiled: July 30, 2008Publication date: February 5, 2009Applicant: AllTranz Inc.Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammel, Jeffery Lynn Howard, Stan Lee Banks
-
Publication number: 20090005352Abstract: The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.Type: ApplicationFiled: June 26, 2007Publication date: January 1, 2009Applicant: XenoPort, Inc.Inventors: Feng Xu, Mark A. Gallop
-
Publication number: 20090005444Abstract: Methods of treating alcohol withdrawal, central pain, anxiety, or pruritus in a patient comprising orally administering a therapeutically effective amount of a propofol prodrug having high oral bioavailability are disclosed.Type: ApplicationFiled: June 18, 2008Publication date: January 1, 2009Applicant: XenoPort, Inc.Inventors: Kenneth C. Cundy, Peter A. Virsik
-
Patent number: 7468360Abstract: Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.Type: GrantFiled: August 8, 2007Date of Patent: December 23, 2008Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Publication number: 20080269324Abstract: A drag may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.Type: ApplicationFiled: August 7, 2006Publication date: October 30, 2008Inventor: Robert R. Rando
-
Publication number: 20080255206Abstract: The present invention relates to the use of one or more retinoid agonists and/or antagonists comprising retinoids with selective Retinoid X Receptor (RXR) agonistic or antagonistic activity alone or in combination with one or more peroxisome proliferator activated receptor (PPAR) ligands for the manufacture of a medicament for the (preferably oral or topical) treatment (this term including prevention/prophylaxis and/or therapy) of one or more manifestations of metabolic syndrome (also known as syndrome X), also called diseases hereinafter, especially from one or more manifestations thereof selected from the group consisting of diabetes type II, obesity, dyslipidemia, hypertension and polyneuropathy, each of which can also be linked with a high risk of cardiovascular diseases. Corresponding methods, the compounds and combinations for use in the treatment of the mentioned diseases and comparable invention embodiments are also described.Type: ApplicationFiled: October 13, 2006Publication date: October 16, 2008Inventor: Werner Bollag
-
Publication number: 20080248101Abstract: A pharmaceutical composition containing fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose reduces food effect. The cellulose derivative represents less than 20 wt. % of the composition. The association of fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enhances the bioavailability of fenofibrate. Also provided is a method for preparing said composition without organic solvent.Type: ApplicationFiled: June 11, 2008Publication date: October 9, 2008Applicant: SOCIETE LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARMInventors: Bruno Criere, Pascal Suplie, Philippe Chenevier
-
Patent number: 7432392Abstract: A therapeutic agent for hyperlipidemia which has no side effects on the liver unlike conventional MTP inhibitors and has excellent MTP inhibitory activity. Also, provided is an ester compound represented by the general formula (1): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 27, 2006Date of Patent: October 7, 2008Assignee: Japan Tobacco Inc.Inventors: Atsushi Hagiwara, Taku Ikenogami, Yasuko Mera, Yukako Sumida, Akio Iida, Toshio Taniguchi, Mitsuru Takahashi
-
Publication number: 20080241070Abstract: Disclosed are redispersible fibrate, such as fenofibrate, dosage forms. Also disclosed are in vitro methods for evaluating the in vivo effectiveness of fibrate, such as fenofibrate, dosage forms. The methods utilize media representative of in vivo human physiological conditions.Type: ApplicationFiled: March 28, 2008Publication date: October 2, 2008Inventors: Tuula A. Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins, Niels P. Ryde